ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer

Keyphrases

• 5-year Survival 25%
• Antiangiogenic Agents 25%
• Antigenic Protein 25%
• Antitumor Agents 25%
• Apoptotic Tumor Cells 25%
• Ascites 25%
• Ascitic Fluid 25%
• Bursa 25%
• C57BL 25%
• Cell Lysate 25%
• Common Cancers 25%
• Epithelial Cells 25%
• Epithelial Ovarian Cancer 100%
• Human Ovarian Cancer Cell 25%
• Immunoblot Analysis 25%
• Lesion Dissemination 25%
• Mimetic Peptide 25%
• Mitogen-activated Protein Kinase 25%
• Ovarian Cancer 25%
• Ovarian Tumor 100%
• Overall Survival Rate 25%
• Phosphoinositide 3-kinase (PI3K) 25%
• Preclinical Animal Models 25%
• Proliferating Cell nuclear Antigen 25%
• Protein Expression 25%
• Secondary Lesions 25%
• Small Vessels 25%
• Survival Pathways 25%
• Syngeneic Model 100%
• Thrombospondin-1 (TSP-1) 25%
• Tissue Hypoxia 25%
• Tumor 50%
• Tumor Burden 25%
• Tumor Cell Apoptosis 100%
• Tumor Growth 100%
• Tumor Size 25%
• Vascular Endothelial Growth Factor 25%
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 25%
• Vascular Remodeling 25%
• Vasculature 25%
• Volume of Fluid 25%

Medicine and Dentistry

• Antiangiogenic 25%
• Anticarcinogen 25%
• Antigen 25%
• Ascites 25%
• Ascites Fluid 25%
• C57BL/6 25%
• Cancer Cell 25%
• Epithelial Cell 25%
• Hypoxemia 25%
• Immunoblotting 25%
• In Vitro 25%
• Krukenberg Tumor 100%
• Malignant Neoplasm 25%
• Mitogen-Activated Protein Kinase 25%
• Neoplasm 75%
• Ovarian Cancer 50%
• Ovarian Tumor 100%
• Overall Survival 25%
• Phosphoinositide 3-Kinase 25%
• Programmed Cell Death 100%
• Proliferating Cell Nuclear Antigen 25%
• Protein Expression 25%
• Survival Rate 50%
• Thrombospondin 1 25%
• Tumor Cell 100%
• Tumor Progression 100%
• Vascular Remodeling 25%
• Vascularity 25%
• Vasculotropin 25%
• Vasculotropin Receptor 2 25%
• Vessel Diameter 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiangiogenic 16%
• Anticarcinogen 16%
• Antigen 16%
• Ascites 33%
• C57BL 6 Mouse 16%
• Cycline 16%
• Hypoxemia 16%
• Malignant Neoplasm 16%
• Mitogen Activated Protein Kinase 16%
• Mouse Model 16%
• Neoplasm 100%
• Ovary Cancer 33%
• Ovary Carcinoma 100%
• Ovary Tumor 100%
• Overall Survival 16%
• Phosphatidylinositol 3 Kinase 16%
• Survival Rate 33%
• Thrombospondin 1 16%
• Tumor Growth 100%
• Vascular Remodeling 16%
• Vasculotropin 16%
• Vasculotropin Receptor 2 16%
• Western Blot 16%